NAFLD
Meeting category
Date(s)
6 May 2022 - 7 May 2022
Location
Barcelona, Spain
Meeting type
Hybrid Workshop
Organizer

Innovations in NAFLD Care Workshop 2022

Related Enduring Materials

Enduring Materials
Innovations in NAFLD Care Workshop (INCBCN) 2023

To read about and register for INCBCN 2023 please click here: https://academicmedicaleducation.com/meeting/innovations-nafld-care-workshop-2023

Virtual Program Book INCBCN 2022
Program

Day 1 - Friday, 6 May 2022

Session 1: NAFLD - Epidemiology and Disease Burden; Measuring a Silent Condition -
Chairs
Jeffrey V. Lazarus, PhD, MIH, MA
Barcelona Institute for Global Health (ISGlobal), Spain / CUNY Graduate School of Public Health and Health Policy, United States
Alina Allen, MD
Mayo Clinic Rochester, United States
Is NAFLD/NASH a Public Health Challenge in 2022?
Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD
The Global NASH Council / Beatty Liver and Obesity Research, Inova Health System, United States
The Liver-Heart Axis – Does NASH Drive Cardiovascular Disease?
Sven Francque, MD, PhD
Antwerp University Hospital, University of Antwerp, Belgium
Fatal Triple – Linking Obesity, Type-2 Diabetes, and NASH
Cyrielle Caussy, MD, PhD
Lyon University and Lyon South Hospital, France
Discussion
Session 2: Screening and Risk-Stratifying for NAFLD – Who and Where? -
Chairs
Kenneth Cusi, MD, FACP, FACE
The University of Florida, United States
Helen Jarvis, MD
Newcastle University, United Kingdom
Clinical Care Pathways for the Risk Stratification of Patients
Emmanuel Tsochatzis, MD, MSc, FEBTM, FRCP, PhD
Royal Free Hospital, United Kingdom
Use of Intelligent Liver Function Testing in General Practice
John Dillon, MB,BS,MD,MRCP(UK),FRCP(Edinburgh)
University of Dundee / Ninewells Hospital, United Kingdom
Why and How to Identify NAFLD in Primary Care?
Jean Muris, MD, PhD
Maastricht University, The Netherlands
Discussion
Session 3: How to Manage Patients with NAFLD in Different Healthcare Facilities -
Chairs
Emmanuel Tsochatzis, MD, MSc, FEBTM, FRCP, PhD
Royal Free Hospital, United Kingdom
John Dillon, MB,BS,MD,MRCP(UK),FRCP(Edinburgh)
University of Dundee / Ninewells Hospital, United Kingdom
The Central Role of Primary Care in the NASH Epidemic: Opportunities and Challenges
Helen Jarvis, MD
Newcastle University, United Kingdom
Nutritionists Perspective: Lifestyle and Behavioral Structured Interventions
Shira Zelber-Sagi, BSc, RD, PhD
University of Haifa / The Tel-Aviv Medical Center, Israel
Pushing for Weight Management: Bariatric Interventions Benefits and Considerations
Jörn M. Schattenberg, MD
Saarland University Medical Center, Germany
Discussion

Day 2 - Saturday, 7 May 2022

Patient Organization Session -
Chair
Jörn M. Schattenberg, MD
Saarland University Medical Center, Germany
Roundtable Discussion: the NAFLD Continuum of Care
Achim Kautz
Kautz5 gUG, Germany
Donna R. Cryer, JD
Global Liver Institute, United States
José Willemse, MSc
Dutch Liver Patients Association, the Netherlands
Session 4: Multidisciplinary Management of NAFLD – How to Manage Our Patients Today? -
Chairs
Jörn M. Schattenberg, MD
Saarland University Medical Center, Germany
Shira Zelber-Sagi, BSc, RD, PhD
University of Haifa / The Tel-Aviv Medical Center, Israel
The Road to Comprehensive Models of Care for NAFLD - What Are the Endpoints?
Jeffrey V. Lazarus, PhD, MIH, MA
Barcelona Institute for Global Health (ISGlobal), Spain / CUNY Graduate School of Public Health and Health Policy, United States
Integrating Non-Invasive Tests for NAFLD in Clinical Practice Outside the Liver Space - Which Test and at What Level?
Alina Allen, MD
Mayo Clinic Rochester, United States
Using the Power of Digital Innovation - Apps Transforming Weight Management
Marcus Ranney, MD
Human Edge, India
Discussion
Industry Session -
Chairs
Jörn M. Schattenberg, MD
Saarland University Medical Center, Germany
Jeffrey V. Lazarus, PhD, MIH, MA
Barcelona Institute for Global Health (ISGlobal), Spain / CUNY Graduate School of Public Health and Health Policy, United States
Roundtable Discussion: Industry Developments Advancing Comprehensive Care Models for NAFLD
Laurent Sandrin, PhD
Echosens, France
Peter Rydqvist, MSc, PharmD
Madrigal Pharmaceuticals, Sweden
Ahsan Shoeb, MBBS, MD, DPMM
Novo Nordisk A/S, Denmark
Lunch
Session 5: Future Pharmacotherapeutics for NASH - Defining Mechanisms, Drug Safety and Efficacy -
Chairs
Sven Francque, MD, PhD
Antwerp University Hospital, University of Antwerp, Belgium
Cyrielle Caussy, MD, PhD
Lyon University and Lyon South Hospital, France
Pharmacotherapy for Obesity - Improving Body Weight and NAFLD
Naim Alkhouri, MD
Arizona Liver Health, United States
How to Use Diabetes Drugs for Liver Benefit in Patients with NAFLD
Kenneth Cusi, MD, FACP, FACE
The University of Florida, United States
Liver-Directed Drugs in the Pipeline for Fibrotic NASH
Stephen Harrison, MD, FACP, FAASLD
University of Oxford / Pinnacle Clinical Research / Summit Clinical Research, United Kingdom / United States
Discussion
Session 6: Roundtable Discussion on the Public Health Roadmap to Comprehensive Care for NAFLD/NASH -
Chairs
Jörn M. Schattenberg, MD
Saarland University Medical Center, Germany
Jeffrey V. Lazarus, PhD, MIH, MA
Barcelona Institute for Global Health (ISGlobal), Spain / CUNY Graduate School of Public Health and Health Policy, United States
Exchanging and Sharing Ideas on the NAFLD/NASH Roadmap Including Social Media and Digital Transformation of Health Care
Roger Green, MBA
SurfingNASH / HEP Dynamics, United States
Kenneth Cusi, MD, FACP, FACE
The University of Florida, United States
Shira Zelber-Sagi, BSc, RD, PhD
University of Haifa / The Tel-Aviv Medical Center, Israel
Marcus Ranney, MD
Human Edge, India
Language